Cirrhosis News and Research

Latest Cirrhosis News and Research

BWH researchers identify cells responsible for fibrosis

Researchers from Brigham and Women's Hospital have identified what they believe to be the cells responsible for fibrosis, the buildup of scar tissue. Fibrotic diseases, such as chronic kidney disease and failure, lung disease, heart failure and cirrhosis of the liver, are estimated to be responsible for up to 45 percent of deaths in the developed world.

2 Dec 2014

New cell therapy offers hope for patients with liver cirrhosis

Liver disease patients could be helped by a new cell therapy to treat the condition.

24 Nov 2014

AGA's journals highlight important updates into treatments for cirrhosis, NAFLD

Cirrhosis and nonalcoholic fatty liver disease (NAFLD) are two serious liver conditions with limited pharmacological treatments. The December issues of AGA's journals -- Clinical Gastroenterology and Hepatology and Gastroenterology -- highlight important updates into treatments for these two debilitating diseases.

23 Nov 2014

Montefiore Medical Center receives $3.5M grant to advance treatment for hepatitis C

Montefiore Medical Center received a $3.5 million grant as part of the $10 million Health Care Innovation Award from the Center for Medicare & Medicaid Services to identify, diagnose and treat people with hepatitis C (HCV).

13 Nov 2014

New treatment regimen for hepatitis C in transplant patients produces promising results

A new treatment regimen for hepatitis C, the most common cause of liver cancer and transplantation, has produced results that will transform treatment protocols for transplant patients, according to research published online today in the New England Journal of Medicine.

12 Nov 2014

Study examines overall survival of patients with chronic HCV infection, cirrhosis

Patients with chronic hepatitis C virus infection and advanced fibrosis or cirrhosis who attained sustained virological response (SVR) had survival comparable with that of the general population, whereas patients who did not attain SVR had reduced survival, according to a study in the November 12 issue of JAMA.

12 Nov 2014

Two new oral medications post-transplant is safe, beneficial for patients with hepatitis C

All patients with hepatitis C who receive a liver transplant will eventually infect their new livers. These transplanted organs then require anti-viral treatment before they become severely damaged. But traditional post-transplant hepatitis C therapy can take up to a year, is potentially toxic and can lead to organ rejection.

11 Nov 2014

Penn researchers show that 23% of patients who survive septic shock return to hospital within 30 days

A diagnosis of septic shock was once a near death sentence. At best, survivors suffered a substantially reduced quality of life.

6 Nov 2014

FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA (ramucirumab) in combination with paclitaxel (a type of chemotherapy) as a treatment for people with advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy.

5 Nov 2014

Common drug could become the future standard of care for HE patients

A common drug used to clean a person's bowels before a colonoscopy could become the future standard of care for patients with acute hepatic encephalopathy (HE), a mental disorientation problem that affects up to one in two cirrhosis patients.

4 Nov 2014

Decaffeinated coffee may benefit liver health

Researchers from the National Cancer Institute report that decaffeinated coffee drinking may benefit liver health. Results of the study published in Hepatology, a journal of the American Association for the Study of Liver Diseases, show that higher coffee consumption, regardless of caffeine content, was linked to lower levels of abnormal liver enzymes. This suggests that chemical compounds in coffee other than caffeine may help protect the liver.

10 Oct 2014

Discovery could lead to treatments for alcohol-related liver diseases

Researchers at the University of Missouri School of Medicine have identified epigenetic protein changes caused by binge drinking, a discovery that could lead to treatments for alcohol-related liver diseases.

9 Oct 2014

Medac Pharma launches Rasuvo (methotrexate) injection for patients with RA, pJIA and psoriasis

Medac Pharma, Inc., a privately held pharmaceutical company, has announced the launch of its lead product Rasuvo (methotrexate) injection for patients with rheumatoid arthritis (RA), poly-articular-course juvenile idiopathic arthritis (pJIA) and psoriasis in the U.S.

6 Oct 2014

Galmed Pharmaceuticals purchases EndoPAT devices, accessories from Itamar Medical

Galmed Pharmaceuticals Ltd. ("Galmed"), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral medication for the treatment of liver diseases and cholesterol gallstones, announced today that it purchased 60 EndoPAT™ devices and accessories from Itamar Medical Ltd.

29 Sep 2014

Magnetic resonance: A good method for detecting and quantifying fats in the liver

Obesity and overweight affect more than half of the population in our Community. Excess weight causes important alterations in the organism, one of which affects liver function. Fat accumulates in the liver producing hepatic steatosis which, in certain circumstances, causes inflammation, fibrosis and finally, cirrhosis.

18 Sep 2014

T-bet protein fights off hepatitis infections

A single protein may tip the balance between ridding the body of a dangerous virus and enduring life-long chronic infection, according to a report appearing in The Journal of Experimental Medicine.

16 Sep 2014

Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Eli Lilly and Company today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival.

15 Sep 2014

Researchers examine whether new drug offers added benefit for patients with chronic HCV

The drug simeprevir has been available since May 2014 for the treatment of adult patients with chronic hepatitis C infection.

9 Sep 2014

Novira completes Phase 1a clinical study of NVR-1221 for treatment of HBV infection

Novira Therapeutics, Inc., a privately held biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection, today announced successful completion of a Phase 1a clinical study of NVR-1221.

4 Sep 2014

Bristol-Myers Squibb launches Daklinza in the UK for treatment of chronic hepatitis C

Bristol-Myers Squibb today announced the launch of Daklinza▼ (daclatasvir) in the UK, a new medicine for the treatment of adult patients with chronic hepatitis C. Daclatasvir, a treatment that works across multiple hepatitis C genotypes, will allow up to 90% of UK patients the option of a potentially curative oral treatment regimen that does not include interferon, a standard of care commonly associated with sustained flu-like side effects.

4 Sep 2014

Cirrhosis News and Research

Latest Cirrhosis News and Research

BWH researchers identify cells responsible for fibrosis

New cell therapy offers hope for patients with liver cirrhosis

AGA's journals highlight important updates into treatments for cirrhosis, NAFLD

Montefiore Medical Center receives $3.5M grant to advance treatment for hepatitis C

New treatment regimen for hepatitis C in transplant patients produces promising results

Study examines overall survival of patients with chronic HCV infection, cirrhosis

Two new oral medications post-transplant is safe, beneficial for patients with hepatitis C

Penn researchers show that 23% of patients who survive septic shock return to hospital within 30 days

FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

Common drug could become the future standard of care for HE patients

Decaffeinated coffee may benefit liver health

Discovery could lead to treatments for alcohol-related liver diseases

Medac Pharma launches Rasuvo (methotrexate) injection for patients with RA, pJIA and psoriasis

Galmed Pharmaceuticals purchases EndoPAT devices, accessories from Itamar Medical

Magnetic resonance: A good method for detecting and quantifying fats in the liver

T-bet protein fights off hepatitis infections

Ramucirumab Phase III study meets primary endpoint in patients with metastatic colorectal cancer

Researchers examine whether new drug offers added benefit for patients with chronic HCV

Novira completes Phase 1a clinical study of NVR-1221 for treatment of HBV infection

Bristol-Myers Squibb launches Daklinza in the UK for treatment of chronic hepatitis C

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Cirrhosis News and Research

Latest Cirrhosis News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in